Tweets
RT @@Gibson_RheumPAC
Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26 https://t.co/nvwl5mNg4k
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
Incretins/GLP-1s are being investigated widely. @RWCSmtg #RWCS26 https://t.co/57JzRJfK8l
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
Most inhibition of inflammation is via the brain. More GLP1 and GIP1 receptors are in the brain, more than the gut. @RWCSmtg #RWCS26 https://t.co/CNzUqteBLg
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
The hx and timeline of GLP1a development. @RWCSmtg #RWCS26 https://t.co/7tPgcRy4Ze
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
Dr. Willa Tsueh taking on hx of GLP-1 agonists. The first ones, Victoza and Tulicity go back to 2010. @RWCSmtg #RWCS26 https://t.co/cKiDCM5xw6
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
#RNL26
Haque @HopkinsRheum
1/2 of Americans will be obese by 2030
"Obesity is common & obesity is expensive"
Adipose tissue - active endocrine organ -> cytokines, chemokines, adipokines
Leads to inflamm axis - risk factor similar to 🚬, higher activity, worse response https://t.co/yQLTpE7reY
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @ericdeinMD
#RNL26
Dx Modification of OA
@Tuhina_Neogi
Challenge in drug develop:
Models in young animal, not like human OA
Trial enrollment in pts w late, establ OA- not early interv tx
Many paths to OA - target mechanism to correct pt
Slow progress of dx, $$
Endpt? Sx or
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @ericdeinMD
#RNL26
Placebo in Rheumatology - STEP talk
Kerschbaumer
What plays role in PBO?
Treatment adherence effect w better background therapy - may appear to be PBO
Impact in globalization of recruitment patterns, affects background PBO
Education of pts bridges gap
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @richardPAconway
Who to screen for RA-ILD is a tricky one. It is not feasible to screen everyone. This is from ACR/Chest 2023 ILD guidelines and is based on identified risk factors. #RNL26 https://t.co/NtAWYCVclJ
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @richardPAconway Disease activity is a strong risk factor for RA-ILD. Particularly for moderate/high disease activity but there appears to be a linear relationship (at least above a certain threshold) #RNL26 https://t.co/ot8ttdmu5G
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
Vasculitis
Sunday’s vasculitis session at RNL26 was a fantastic update on inflamed blood vessels, large and small, by two experts in the field.
https://t.co/ueg3yJDMu4 https://t.co/8uiI9A5G8x
Links:
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @richardPAconway
Lifetime risk of ILD by RA/sex/MUC5B status. We can see the synergistic effect. Also note RA>MUC5B in general. #RNL26 https://t.co/L5MOVVGIt3
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @richardPAconway
MUC5B is strong risk factor for RA-ILD. Specifically for UIP. Associated with both older-onset RA, and ILD earlier following RA presentation. #RNL26 https://t.co/qeLp1BqOEM
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @ericdeinmd
RA-ILD #RNL26
Jeff Sparks
MTX and ILD
- Rare MTX-induced pneumonitis. 7 cases in n=4786 (0.3% cases) vs <0.1 on PBO, rare diff from ILD
- No increase in incident ILD - meta-analysis of 7 studies show OR 0.49 https://t.co/k2XeAzBsYB
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
RT @ericdeinmd
#RNL26 RA-ILD Jeff Sparks
ILD pooled prevalence 0.11
Sparks: "prevalence is high but not so high that we don't screen everyone," means lots of subclinical ILD
Subtypes:
UIP 50-60%, fibrotic
NSIP 30-40%, inflammatory
Less common: LIP, DIP, RB-ILD, DAD
Dr. John Cush @RheumNow ( View Tweet )
6 months 2 weeks ago
